TY - JOUR T1 - Cefotaxime therapy of serious infections with multiresistant gram-negative bacilli36603 JF - Scand.J.Infect.Dis. Y1 - 1982 A1 - Clumeck,N. A1 - Van Laethem,Y. A1 - R. Vanhoof A1 - George,C. A1 - Rapin,M. A1 - Butzler,J.P. KW - 0 KW - a KW - Adult KW - adverse effects KW - Aged KW - Agent KW - Agents KW - Ampicillin KW - Anti-Bacterial Agents KW - article KW - bacteria KW - Bacterial Infections KW - blood KW - Cefazolin KW - Cefotaxime KW - Cephalothin KW - Creatinine KW - Drug Resistance,Microbial KW - drug therapy KW - evidence KW - Female KW - function KW - Humans KW - im KW - Improvement KW - INFECTION KW - infections KW - IS KW - journal KW - Male KW - middle aged KW - observed KW - pathogen KW - Patient KW - patients KW - Print KW - RENAL KW - Respiratory KW - Respiratory Tract Infections KW - SB - IM KW - septicemia KW - therapeutic use KW - Therapy KW - Tobramycin KW - Urinary KW - urinary tract KW - urinary tract infection KW - Urinary Tract Infections AB - 33 patients with serious gram-negative bacillary infections were treated with cefotaxime. In patients with normal renal function the dose varied between 1.5 to 4 g/day. 17 patients had urinary tract infections, 5 respiratory tract infections, 1 combined urinary tract infection and respiratory tract infection, and 10 miscellaneous infections. 16 patients had septicemia. 25 infections were due to pathogens resistant in vitro to ampicillin, cephalothin, gentamicin and/or tobramycin. 15 infections had failed to respond to ampicillin, cefazolin, gentamicin or tobramycin therapy. 32/33 patients responded favourably to cefotaxime (cure or improvement) but 4 patients developed superinfection with cefotaxime-resistant bacteria. No evidence of nephrotoxicity was observed except for a transient moderate rise in creatinine in one patient VL - 14 CP - 1 U1 - 36603 ER -